The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors
Abstract
AT1R (angiotensin type 1 receptor) and AT2R (angiotensin type 2 receptor) are well known to be involved in the complex cardiovascular actions of AngII (angiotensin II). However, shorter peptide fragments of AngII are thought to have biological activity in their own right and elicit effects that oppose those mediated by AngII. In the present study, we have used HEK (human embryonic kidney)-293 cells stably transfected with either AT1R or AT2R to perform a systematic analysis of binding affinities of all the major angiotensin peptides. Additionally, we tested the novel AT2R agonist Compound 21, as well as the MasR (Mas receptor) agonist and antagonist AVE0991 and A-779 respectively, for their ability to bind to AT1R or AT2R. Candesartan, CGP42214 and PD123319 were used as reference compounds. Binding studies using 125I-[Sar1Ile8]AngII on the AT1R-transfected HEK-293 cells revealed only AngII, AngIII [angiotensin III; angiotensin-(2–8)] and candesartan to have high affinity for AT1R. In the AT2R-transfected HEK-293 cells, competition for 125I-[Sar1Ile8]AngII binding was observed for all ligands except candesartan, AVE0991 and A-779, the latter two compounds having negligible affinity at either AT1R or AT2R. The rank order of affinity of ligands at AT2R was CGP42112>AngII≥AngIII>Compound 21≥PD123319≫AngIV [angiotensin IV; angiotensin-(3–8)]>Ang-(1–7) [angiotensin-(1–7)]. Of note, although AngIV and Ang-(1–7) exhibited only modest affinity at AT2R compared with AngII, these two angiotensin peptides, together with AngIII, had substantial AT2R selectivity over AT1R. Collectively, our results suggest that shorter angiotensin peptides can act as endogenous ligands at AT2R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Preliminary biochemical characterization of two angiotensin II receptor subtypes
Whitebread, S., Mele, M., Kamber, B., & de Gasparo, M. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92133-5 · Cited by 777
RICE, G. I., THOMAS, D. A., GRANT, P. J., TURNER, A. J., & HOOPER, N. M. (2004) · Biochemical Journal · doi:10.1042/bj20040634 · Cited by 619
Nonpeptide angiotensin II receptor antagonists
Timmermans, P. B. M. W. M., Wong, P. C., Chiu, A. T., & Herblin, W. F. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90498-h · Cited by 549
Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase
Albiston, A. L., McDowall, S. G., Matsacos, D., Sim, P., Clune, E., Mustafa, T., Lee, J., Mendelsohn, F. A. O., Simpson, R. J., Connolly, L. M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100512200 · Cited by 461
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Recent advances in the angiotensin‐converting enzyme 2–angiotensin(1–7)–Mas axis
Santos, R. A. S., Ferreira, A. J., & Simões e Silva, A. C. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2008.042002 · Cited by 432
Santos, R. A. S., Campagnole-Santos, M. J., & Andrade, S. P. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00138-5 · Cited by 380
Subclasses of angiotensin II binding sites and their functional significance.
Dudley, D. T., Panek, R. L., Major, T. C., Lu, G. H., Bruns, R. F., Klinkefus, B. A., Hodges, J. C., & Weishaar, R. E. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09488-x · Cited by 374
Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist
Wan, Y., Wallinder, C., Plouffe, B., Beaudry, H., Mahalingam, A. K., Wu, X., Johansson, B., Holm, M., Botoros, M., Karlén, A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049715t · Cited by 330
Santos, R. A. S., Campagnole-Santos, M. J., Baracho, N. C. V., Fontes, M. A. P., Silva, L. C. S., Neves, L. A. A., R. Oliveira, D., Caligiorne, S. M., Rodrigues, A. R. V., Gropen, C., et al. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90104-x · Cited by 286
Kaschina, E., Grzesiak, A., Li, J., Foryst-Ludwig, A., Timm, M., Rompe, F., Sommerfeld, M., Kemnitz, U. R., Curato, C., Namsolleck, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.784868 · Cited by 261
The AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
What?s new in the renin-angiotensin system?: The angiotensin IV/AT4 receptor
Chai, S. Y., Fernando, R., Peck, G., Ye, S. Y., Mendelsohn, F. A. O., Jenkins, T. A., & Albiston, A. L. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4246-1 · Cited by 237
AT2 receptors: Functional relevance in cardiovascular disease
Jones, E. S., Vinh, A., McCarthy, C. A., Gaspari, T. A., & Widdop, R. E. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.009 · Cited by 237
Self-citationImpairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
Santos, R. A. S., Castro, C. H., Gava, E., Pinheiro, S. V. B., Almeida, A. P., de Paula, R. D., Cruz, J. S., Ramos, A. S., Rosa, K. T., Irigoyen, M. C., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000215289.51180.5c · Cited by 237
Angiotensin AT2 receptors: cardiovascular hope or hype?
Widdop, R. E., Jones, E. S., Hannan, R. E., & Gaspari, T. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705448 · Cited by 223
Self-citationWalters, P. E., Gaspari, T. A., & Widdop, R. E. (2005) · Hypertension · doi:10.1161/01.hyp.0000160325.59323.b8 · Cited by 206
Self-citationAVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1–7) on the Endothelium
Wiemer, G., Dobrucki, L. W., Louka, F. R., Malinski, T., & Heitsch, H. (2002) · Hypertension · doi:10.1161/01.hyp.0000037979.53963.8f · Cited by 199
Benter, I. F., Yousif, M. H. M., Anim, J. T., Cojocel, C., & Diz, D. I. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00632.2005 · Cited by 187
Muthalif, M. M., Benter, I. F., Uddin, M. R., Harper, J. L., & Malik, K. U. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37208-8 · Cited by 175
de Castro, C. H., Souza dos Santos, R. A., Ferreira, A. J., Bader, M., Alenina, N., & Pinto de Almeida, A. (2005) · Hypertension · doi:10.1161/01.hyp.0000175813.04375.8a · Cited by 168
Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E–Deficient Mice
Tesanovic, S., Vinh, A., Gaspari, T. A., CASLEY, D. J., & Widdop, R. E. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.204453 · Cited by 151
Self-citationBarber, M., Sampey, D. B., & Widdop, R. E. (1999) · Hypertension · doi:10.1161/01.hyp.34.5.1112 · Cited by 148
Self-citationPadia, S. H., Howell, N. L., Siragy, H. M., & Carey, R. M. (2005) · Hypertension · doi:10.1161/01.hyp.0000196950.48596.21 · Cited by 146
Bosnyak, S., Welungoda, I., Hallberg, A., Alterman, M., Widdop, R. E., & Jones, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00575.x · Cited by 140
Self-citationD’Amore, A., Black, M. J., & Thomas, W. G. (2005) · Hypertension · doi:10.1161/01.hyp.0000193504.51489.cf · Cited by 133
Self-citationAngiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs
Santos, R. A. S., Ferreira, A. J., Pinheiro, S. V. B., Sampaio, W. O., Touyz, R. M., & Campagnole‐Santos, M. J. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.8.1019 · Cited by 132
Lemos, V. S., Silva, D. M. R., Walther, T., Alenina, N. V., Bäder, M., & Santos, R. A. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000175237.41573.63 · Cited by 128
Angiotensin 1–7 Induces Bradykinin-Mediated Relaxation in Porcine Coronary Artery
Gorelik, G. J., Carbini, L. A., & Scicli, A. G. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37600-1 · Cited by 100
Thomas, W. G., Motel, T. J., Kule, C. E., Karoor, V., & Baker, K. M. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.10.0179 · Cited by 95
Self-citationPharmacological Effects of AVE 0991, a Nonpeptide Angiotensin‐(1–7) Receptor Agonist
Santos, R. A. S., & Ferreira, A. J. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00239.x · Cited by 85
Padia, S. H., Kemp, B. A., Howell, N. L., Siragy, H. M., Fournié‐Zaluski, M., Roques, B. P., & Carey, R. M. (2006) · Hypertension · doi:10.1161/01.hyp.0000254833.85106.4d · Cited by 79
Miura, S.-I., & Karnik, S. S. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917030-00013 · Cited by 78
Souza, A. M. D., Lopes, A. G., Pizzino, C. P., Fossari, R. N., Miguel, N. C. O., Cardozo, F. P., Abi-Abib, R. D. C., Fernandes, M. S., Santos, D. P. A., & Caruso‐Neves, C. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.03.005 · Cited by 74
Lara, L. S., Cavalcante, F., Axelband, F., Souza, A. M. D., Lopes, A. G., & Caruso‐Neves, C. (2006) · Biochemical Journal · doi:10.1042/bj20051455 · Cited by 72
Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice
Vinh, A., Widdop, R. E., Drummond, G. R., & Gaspari, T. A. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm021 · Cited by 70
Self-citationFunctional Reconstitution of the Angiotensin II Type 2 Receptor and GiActivation
Hansen, J. L., Servant, G., Baranski, T., Fujita, T., Iiri, T., & Sheikh, S. P. (2000) · Circulation Research · doi:10.1161/01.res.87.9.753 · Cited by 69
Faure, S., Chapot, R., Tallet, D., Javellaud, J., Achard, J., & Oudart, N. (2006) · PubMed · Cited by 61
van Esch, J. H. M., Oosterveer, C. R., Batenburg, W. W., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.042 · Cited by 47
Faure, S., Bureau, A., Oudart, N., Javellaud, J., Fournier, A. E., & Achard, J. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e32830dd5ee · Cited by 43
N- and C-terminal structure–activity study of angiotensin II on the angiotensin AT2 receptor
Bouley, R., Pérodin, J., Plante, H., Řihakova, L., Bernier, S. G., Maletı́nská, L., Guillemette, G., & Escher, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01549-5 · Cited by 35
Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells
Mukoyama, M., Horiuchi, M., Nakajima, M., Pratt, R. E., & Dzau, V. J. (1995) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03586-v · Cited by 28
Synthesis and AT2 receptor‐binding properties of angiotensin II analogues
Rosenström, U., Sköld, C., Lindeberg, G., Botros, M., Nyberg, F., Hallberg, A., & Karlén, A. (2004) · Journal of Peptide Research · doi:10.1111/j.1399-3011.2004.00184.x · Cited by 26
Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma
Vinh, A., Widdop, R. E., Chai, S. Y., & Gaspari, T. A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.12.042 · Cited by 24
Self-citation
Cited by
Singh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Counter-regulatory renin–angiotensin system in cardiovascular disease
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0244-8 · Cited by 561
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Metadata
- Authors
- Bosnyak, S., Jones, E. S., Christopoulos, A., Aguilar, M.-I., Thomas, W. G., & Widdop, R. E.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2011-06-07
- Volume
- 121
- Issue
- 7
- Pages
- 297-303
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W1512110535
- Cited by
- 288
- References
- 48
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.